<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070096</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000329992</org_study_id>
    <secondary_id>MSKCC-03041</secondary_id>
    <secondary_id>NCI-6022</secondary_id>
    <nct_id>NCT00070096</nct_id>
  </id_info>
  <brief_title>Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors</brief_title>
  <official_title>A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well ixabepilone works in treating patients with&#xD;
      metastatic germ cell tumors that are refractory to cisplatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of ixabepilone in patients with metastatic cisplatin-refractory&#xD;
           germ cell tumors.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study within 1.3-4&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Extragonadal Germ Cell Tumor</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed germ cell tumor (GCT) (seminoma or non-seminoma) meeting the&#xD;
             following criteria:&#xD;
&#xD;
               -  Measurable metastatic disease by one of the following methods:&#xD;
&#xD;
                    -  Radiography&#xD;
&#xD;
                         -  If eligibility is defined by measurable disease only, there must be at&#xD;
                            least 1 site that has not been previously irradiated&#xD;
&#xD;
                    -  Alpha-fetoprotein greater than 15 ng/mL and/or ÃŸ-human chorionic&#xD;
                       gonadotropin greater than 2.2 mIU/L&#xD;
&#xD;
          -  Previously treated progressive disease meeting 1 of the following criteria:&#xD;
&#xD;
               -  Not a candidate for potentially curative therapy OR has already received&#xD;
                  high-dose chemotherapy regimens (prior paclitaxel allowed)&#xD;
&#xD;
               -  Deemed to be cisplatin-refractory after prior cisplatin-based regimen AND does&#xD;
                  not want to have potentially curative high-dose therapy (mediastinal or primary&#xD;
                  refractory GCT)&#xD;
&#xD;
               -  Prior treatment with 1 cisplatin-based regimen (primary mediastinal&#xD;
                  nonseminomatous GCT)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
          -  SGOT no greater than 2 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.2 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent experimental or commercial anticancer medications or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gnanamba V. Kondagunta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>June 21, 2013</last_update_submitted>
  <last_update_submitted_qc>June 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>testicular seminoma</keyword>
  <keyword>testicular choriocarcinoma and embryonal carcinoma</keyword>
  <keyword>testicular choriocarcinoma and seminoma</keyword>
  <keyword>testicular choriocarcinoma and teratoma</keyword>
  <keyword>testicular choriocarcinoma and yolk sac tumor</keyword>
  <keyword>testicular choriocarcinoma</keyword>
  <keyword>testicular embryonal carcinoma and seminoma</keyword>
  <keyword>testicular embryonal carcinoma and teratoma with seminoma</keyword>
  <keyword>testicular embryonal carcinoma and teratoma</keyword>
  <keyword>testicular embryonal carcinoma and yolk sac tumor with seminoma</keyword>
  <keyword>testicular embryonal carcinoma and yolk sac tumor</keyword>
  <keyword>testicular embryonal carcinoma</keyword>
  <keyword>testicular yolk sac tumor and teratoma with seminoma</keyword>
  <keyword>testicular yolk sac tumor and teratoma</keyword>
  <keyword>testicular yolk sac tumor</keyword>
  <keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>recurrent extragonadal seminoma</keyword>
  <keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>stage IV extragonadal seminoma</keyword>
  <keyword>recurrent extragonadal germ cell tumor</keyword>
  <keyword>testicular immature teratoma</keyword>
  <keyword>testicular mature teratoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

